Ascletis announces u.s. fda clearance of ind application for its oral small molecule il-17 inhibitor, asc50, for the treatment of psoriasis

-- asc50 is an in-house discovered and developed oral small molecule interleukin-17 (il-17) inhibitor for the treatment of multiple autoimmune and inflammatory diseases, including psoriasis . -- following oral dosing in non-human primates, asc50 demonstrated higher drug exposure, longer half-life and lower clearance than an oral small molecule il-17 inhibitor comparator, which is currently in the clinical development.
ASC Ratings Summary
ASC Quant Ranking